Skip to main content
logo
Hinova Pharmaceuticals Inc. (SHA:688302)
China flag China · Delayed Price · Currency is CNY
35.45
+2.37 (7.16%)
At close: Nov 5, 2026

Hinova Pharmaceuticals Financials Overview

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
82.8520.470.37-1.65-
Revenue Growth
250.91%5480.11%----
Gross Profit
79.7120.190.03-0.88-
Operating Income
-174.02-173.51-227.91-336.69-347.87-345.27
Net Income
-138.63-137.25-199.5-294.16-301.51-306.18
Earnings Per Share
-1.41-1.39-2.01-2.97-3.32-4.12
EPS Growth
------

Revenue by Geography
Chart
Fiscal Year
FY 2025
Period EndingDec '25
China
20.47
Overseas
0
Total
20.47

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
725.86857.93843.931,1041,568901.22
Total Debt
103.79105.899.0512.8535.763.91
Net Cash (Debt)
622.07752.04834.881,0911,532897.31
Net Cash Growth
-23.24%-9.92%-23.48%-28.79%70.74%-21.16%
Net Cash Per Share
6.337.628.4111.0216.8712.07

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-125.49-108.88-187.08-255.51-314.92-227.82
Capital Expenditures
-48.37-82.89-89.55-99.18-69.21-19.77
Free Cash Flow
-173.86-191.76-276.63-354.68-384.13-247.6
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
96.21%98.62%8.43%-53.57%-
Operating Margin
-210.05%-847.65%-62127.45%--21072.49%-
Pretax Margin
-167.33%-670.50%-54379.48%--18264.53%-
Profit Margin
-167.34%-670.51%-54382.81%--18264.53%-
FCF Margin
-209.86%-936.81%-75410.46%--23269.07%-

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
42.37237.848289.18-2418.38-